TG Therapeutics Revenue and Competitors

Claim your profile

Location

$205M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • TG Therapeutics's estimated annual revenue is currently $152k per year.(i)
  • TG Therapeutics received $18.1M in venture funding in March 2014.
  • TG Therapeutics's estimated revenue per employee is $537
  • TG Therapeutics's total funding is $205M.

Employee Data

  • TG Therapeutics has 283 Employees.(i)
  • TG Therapeutics grew their employee count by -28% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$2.1M3343%N/AN/A
#2
$32.9M212-10%N/AN/A
#3
$0.5M6-14%$10MN/A
#4
$7.5M3911%$51.6MN/A
#5
$4.3M31-9%$3.3MN/A
#6
$6M3922%N/AN/A
#7
$4.2M27-16%N/AN/A
#8
$0.7M9-18%$3.2MN/A
#9
$57M3684%N/AN/A
#10
$115.6M9941%$61MN/A

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs to develop IRAK4 inhibitors, and anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City and is traded on NASDAQ under the ticker symbol "TGTX".

keywords:Biotechnology,Cleantech,Healthcare,Marketing,Pharmaceuticals,Wind Power

$205M

Total Funding

283

Number of Employees

$152k

Revenue (est)

-28%

Employee Growth %

N/A

Valuation

N/A

Accelerator

TG Therapeutics News

2022-04-19 - TG Therapeutics: Can The Company Successfully Turn Around?

If you are familiar with the firm, I suggest that you skip to the subsequent section. Operating out of New York, TG Therapeutics is focused on...

2022-04-17 - TG Therapeutics: I May Double Down Again

Given all my analysis of TG Therapeutics, I am seriously debating doubling down at the lowest price possible for TGTX stock. Read why here.

2022-04-17 - TG Therapeutics, Inc. (NASDAQ:TGTX) Given Consensus Recommendation of “Hold” by Brokerages

Read TG Therapeutics, Inc. (NASDAQ:TGTX) Given Consensus Recommendation of “Hold” by Brokerages at Defense World.

2021-11-04 - TG Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results

NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the third quarter ended September 30, 2021 and recent company developments, along with a business outlook for the remainder of 2021. Michael S. Weiss, the Company's Chairma ...

2021-11-04 - TG Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results - Form 8-K

TG Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results Conference call to be held today, Thursday, November 4, 2021 at 8:30 AM ET New York, NY, (November 4, 2021) - TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the third quart ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$79.1M28395%N/A
#2
$84.1M283N/AN/A
#3
$75.6M2836%N/A
#4
$84.1M2832%N/A
#5
$65.4M28323%N/A

TG Therapeutics Funding

DateAmountRoundLead InvestorsReference
2014-03-13$18.1MUndisclosedArticle